US 10905690
Treatment of congenital adrenal hyperplasia
granted A61KA61K31/427A61K31/4985
Quick answer
US patent 10905690 (Treatment of congenital adrenal hyperplasia) held by Neurocrine Biosciences, Inc. expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Neurocrine Biosciences, Inc.
- Grant date
- Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K31/427, A61K31/4985, A61K31/519, A61P